PRKCB and B-cell chronic lymphocytic leukemia: Among the alterations related to this signaling, PRKCB mutation is the only alteration associated with the prognosis (Figure 2A) A phase I trial using a selective PRKCB inhibitor for chronic lymphocytic leukemia is being conducted (NCT03492125).